



New Insights into Gut Hormones and Intestinal Diseases

Guest Editor:

Dr. Hannelouise Kissow
University of Copenhagen,
Faculty of Health Sciences,
Copenhagen, Denmark

Deadline for manuscript
submissions:
closed (31 January 2021)

Message from the Guest Editor

It has been evident for some years now that the intestinotrophic hormone glucagon-like peptide-2 (GLP-2) secreted from the entero-endocrine L cells, has therapeutic potential in treating intestinal diseases. Indeed, the GLP-2 analogue teduglutide is available for the treatment of short bowel syndrome. However, in recent years, it has been recognized that this is probably not the only hormone secreted from the gut implicated in either the pathogenesis or the adaptive and regenerating response in the intestines.

In this Special Issue, we wish to focus on all new aspects of the topic of gut hormones and intestinal diseases. Intestinal diseases in this setting include a wide range of conditions, such as short bowel syndrome, inflammatory bowel diseases, cancer, inherited diseases, and intestinal toxicities from other treatments. Suggested topics could be how intestinal disease influences the secretion of gut hormones; if and how these hormones contribute to the pathophysiology, and if the manipulation of gut hormone secretion modifies disease control.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)